MarketsandMarkets

Isothermal Nucleic Acid Amplification Technology (INAAT) Market Worth $1,651 Million by 2018

The report “Isothermal Nucleic Acid Amplification Technology (INAAT) Market by Application (Infectious Diseases, Blood Screening, Research), Products (Instruments, Reagents), End-User (Hospital, Reference Laboratories, Other) - Global Forecast to 2018”, The global isothermal nucleic acid amplification technology (INAAT) market is poised to reach $1,651 million by 2018 at a CAGR of 13.5% during the forecast period.

 

Pune, India -- (SBWIRE) -- 03/02/2016 -- Browse 31 market data tables and 53 figures spread through 215 pages and in-depth TOC on "Isothermal Nucleic Acid Amplification Technology (INAAT) Market"

http://www.marketsandmarkets.com/Market-Reports/isothermal-nucleic-acid-amplification-technologies-inaat-market-839.html

Early buyers will receive 10% customization on this report.

The increasing demand for enhanced molecular testing using INAAT as well as rising incidence of infectious diseases is driving market growth over the conventional thermal polymerase chain reaction (PCR) technology.

In addition to increasing population suffering from infectious disease and cancer, promise for less expensive molecular testing using INAAT, better throughput in gene amplification, and advent of novel technologies such as Loop-Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA) and Helicase Dependent Amplification (HDA) play pivotal role in propelling market momentum. On the other hand, inadequate advanced infrastructure and higher dependency on convention method (PCR technology) restrict market growth globally.

Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=839

Amongst various applications of INAAT, prognosis and diagnosis of infectious disease allows a huge scope for market penetration of novel isothermal technologies such as Loop-Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA) and Helicase Dependent Amplification (HDA) among others. Infectious disease application market, especially sexually transmitted disease (STD) and hepatitis A & B, is expected to witness a double digit growth rate during the forecast period. Moreover, blood screening application is also expected to be a significant revenue pocket of INAAT due to increasing practice of mandatory testing of donated blood at blood donation unit to ensure the quality of blood sample.

End-users analysis identified reference laboratory as a potential segment ensuring a rapid growth of various isothermal amplification technologies in different complex molecular testing; whereas, technology roadmap analysis expected a rapid adoption of single miniaturized devices in the global molecular diagnostics industry.

Various private investors, venture capital firms (Bill & Melinda Gates Foundation, Welcome Trust), and public funding bodies (the National Institutes of Health and the Centers for Disease Control and Prevention) were found to be significant investors encouraging speedy penetration of advanced isothermal technologies. On the other hand, demand side analysis considered portability and affordability the major factors contributing the competitive edge to isothermal technologies as compared to convention PCR technology.

Get The Sample Pages:
http://www.marketsandmarkets.com/requestsample.asp?id=839

Increasing prevalence rate of infectious diseases and significant adoption of novel technologies are expected to ensure a double digit growth in emerging nations, especially in India, China, South Africa, Singapore, and Middle East. However, INAAT in developed countries is also expected to witness a steady grow in the diagnosis of various infectious diseases such as healthcare-associated infections and sexually transmitted diseases.

The key players in the market include Alere, Inc. (U.S.), Becton, Dickinson & Company (U.S.), BioHelix (U.S.), bioMerieux (France), Hologic Gene-Probe (U.S.), and QIAGEN (The Netherlands).

About MarketsandMarkets
MarketsandMarkets is world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Subscribe Reports from Healthcare Domain @ http://www.marketsandmarkets.com/Subscription.html

Contact:
Mr. Rohan
Unit No. 802, 8th Floor,
Tower - 7, Magarpatta City SEZ,
Hadapsar, Pune – 411013,
Maharashtra, India.
Tel: +1-888-6006-441.
Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets